Authors
Latest:
Building a Plan for Digital Transformation in Medical AffairsLeslie Rotz and Todd Parker outline four major steps in the Medical Affairs digital transformation journey.
Latest:
PREP Act Protections for COVID-19 Vaccine LiabilityHow PREP Act protections will apply to potential COVID-19 vaccine-related claims.
Latest:
Measuring Speaker Campaign EffectivenessSales and marketing effectiveness of speaker programs is often one of the least understood aspects in the industry. Yet, pharma brands spent over $12.5 billion in 2022 to engage and influence with HCP-to-HCP activities. CMS’s Open Payments data is an overlooked tool to get greater visibility and create more strategic opportunities—while also enriching compliance. This paper explores how to filter and pinpoint critical data sets using browser-based technology to gain marketing insights from this data and measure competitiveness.
Latest:
Navigating Disruption in the Metapharma EraAs the life sciences industry enters this next stage of growth, capitalizing on AI and digital transformation will be key to propelling innovation and ensuring that companies are prepared to tackle the challenges ahead.
Latest:
The Top Priority for Sales Leaders: Improving Sales Enablement and Training in PharmaAddressing key challenges in the modern sales sector requires a fundamental shift in training strategies.
Latest:
Fast-Tracking Development: How Life Sciences Will Drive Speed in 2025Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development with an emphasis on getting new treatments in the hands of doctors and patients.
Latest:
Anchoring HEOR Evidence Generation in the Challenge from the MarketHEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.
Latest:
Purposeful Partnerships for Post-COVID EraPharma should be the ‘glue’ that bonds healthcare organizations together to solve society’s most pressing challenges.
Latest:
An Integrated Patient Advocacy Strategy With Transparent CommunicationA roadmap for cohering patient perspectives.
Latest:
How a Top Pharma Pressure Tests a New Platform to Unify Diverse R&D Data AnalyticsJune 24, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST Rafael Fernandez, PhD, Associate Director-Merck & Co. IT, and Gottfried Schroeder, PhD, Associate Principal Scientist at Merck & Co. (Quantitative Biosciences), join PerkinElmer’s Christof Gaenzler, PhD, for a discussion of how they conducted in-depth testing of a new data analytics workflow to streamline data capture and analysis across diverse formats covering a wide range of biochemical, biophysical and cellular assay types.
Latest:
mRNA Technology: First COVID-19, Now CancerHaving proved its efficacy against COVID-19, mRNA technology is positioned to combat another insidious human adversary: cancer.
Latest:
Comparing Registry and Electronic Health Record Data for Real-World Evidence Generation: Heart Failure as a Case StudyContrasting the view of heart failure patients as seen from the perspectives of two large but distinct sources of real-world data: the Veradigm Cardiology Registry and Practice Fusion
Latest:
Closing the Gaps in Pre-Approval Information Exchange to Accelerate Product Success and Patient AccessGaps remain in the pre-approval information process leave payers without all of the information they need to make the proper decisions.
Latest:
Pfizer Announces Agreement with Trump Administration to Lower Prices, Join TrumpRx, and Avoid TariffsDetails of the agreement are confidential, but it reportedly fulfills the requirements President Trump set forth in a July 31st letter to the company.
Latest:
Fast-Tracking Development: How Life Sciences Will Drive Speed in 2025Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development with an emphasis on getting new treatments in the hands of doctors and patients.
Latest:
National Recovery Month is a Time for ActionWith the headlines focused on COVID-19, many may have forgotten about the escalating epidemic of substance use disorder. National Recovery Month is a time to bring this issue back to the top of the agenda, raise awareness, and drive action, writes Richard Pops, CEO of Alkermes.
Latest:
Bridging the Health Equity Gap in Clinical DevelopmentThe COVID-19 pandemic has exposed global health inequities and is driving life sciences companies to establish strategies and better leverage data to address systemic causes and improve equity in access to healthcare innovations, particularly in clinical trials.
Latest:
Escaping the “Valley of Death:” The Funding Process for Biotechnology CompaniesChristopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.
Latest:
7 Proven Digital Programs to Supercharge Pharma Value Chain This YearEach program strengthens the pharma value chain, impacting the core areas of clinical development, supply chain, and manufacturing and commercial engagement.
Latest:
The Growth of International Arbitration in the Life Sciences SectorIn an unpredictable world, international life sciences collaborations can lead to misunderstandings and enforcement challenges, making an effective dispute resolution mechanism an essential risk management tool.
Latest:
A New Era in Clinical TrialsCurrent industry challenges present an opportunity for innovation and the adoption of new solutions, particularly in addressing barriers related to patient recruitment, engagement, and retention.
Latest:
Revitalizing Mature Pharma Brands: 5 Winning StrategiesStrategies that can help maintain and grow your market share. Plus how to adapt to new competitive pressures and evolving customer needs.
Latest:
A Risk-Reward Reset: Getting Serious About Social MediaAs the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?
